Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ELDN
stocks logo

ELDN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.202
-78.67%
--
--
-0.250
+212.5%
--
--
-0.257
+97.44%
Estimates Revision
The market is revising No Change the revenue expectations for Eledon Pharmaceuticals, Inc. (ELDN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -41.33%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-41.33%
In Past 3 Month
Wall Street analysts forecast ELDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELDN is 7.75 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ELDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELDN is 7.75 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.590
sliders
Low
4.00
Averages
7.75
High
10.00
Current: 1.590
sliders
Low
4.00
Averages
7.75
High
10.00
Guggenheim
Buy
maintain
$9 -> $8
2025-11-18
Reason
Guggenheim
Price Target
$9 -> $8
2025-11-18
maintain
Buy
Reason
Guggenheim lowered the firm's price target on Eledon Pharmaceuticals to $8 from $9 and keeps a Buy rating on the shares following the Q3 report last week. In addition to "routine incrementally positive adjustments," the firm is also incorporating the dilution from the recent fund raising, the analyst tells investors.
Craig-Hallum
NULL -> Buy
initiated
$12
2025-07-25
Reason
Craig-Hallum
Price Target
$12
2025-07-25
initiated
NULL -> Buy
Reason
Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target.
Craig-Hallum
initiated
$12
2025-07-25
Reason
Craig-Hallum
Price Target
$12
2025-07-25
initiated
Reason
As previously reported, Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target. Eledon is developing tegoprubart to address the need for a new SOC in immunosuppression for kidney transplant patients, as current therapies cause kidney damage as a side effect, contributing to kidney graft failure after 10-15 years. The firm notes Tegoprubart's advantages support its potential to be the new SOC for kidney transplantation, which is a multi-billion dollar market opportunity, and it has broad utility in other organ transplant settings. Craig-Hallum sees opportunity for significant share appreciation with upcoming data catalysts in kidney transplantation including a Phase Ib update at WTC on August 6th, with readthrough to the Phase II topline readout in November, which represents a major de-risking event.
H.C. Wainwright
Yi Chen
initiated
$9
2025-06-19
Reason
H.C. Wainwright
Yi Chen
Price Target
$9
2025-06-19
initiated
Reason
H.C. Wainwright analyst Yi Chen assmed coverage of Eledon Pharmaceuticals with a Buy rating and $9 price target. Eledon is a clinical-stage biotechnology company focused on the development of an antibody targeting the CD40 ligand to prevent the rejection of transplanted organs and to treat neuroinflammation, the analyst tells investors in a research note. The firm says interim results from the Phase 1b trial demonstrated the company's lead candidate tegoprubart is generally safe and well tolerated in patients undergoing de novo kidney transplantation.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Eledon Pharmaceuticals Inc (ELDN.O) is -1.66, compared to its 5-year average forward P/E of -2.17. For a more detailed relative valuation and DCF analysis to assess Eledon Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.17
Current PE
-1.66
Overvalued PE
-0.72
Undervalued PE
-3.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
6.09
Undervalued EV/EBITDA
-9.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 138.83% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ELDN News & Events

Events Timeline

(ET)
2025-11-18
16:11:16
Eledon Pharmaceuticals announces initial findings from tegoprubart trial
select
2025-11-14 (ET)
2025-11-14
17:01:40
Eledon Pharmaceuticals announces Q3 earnings per share of 21 cents, below consensus estimate of 25 cents.
select
2025-11-12 (ET)
2025-11-12
07:58:53
Eledon sets price for 15.15 million shares at $1.65 in public offering with underwriters
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-15SeekingAlpha
Eledon Pharmaceuticals Reports GAAP EPS of -$0.21

  • Q3 Financial Performance: Eledon Pharmaceuticals reported a Q3 GAAP EPS of -$0.21, indicating a loss for the quarter.

  • Cash Position: As of September 30, 2025, the company had $93.4 million in cash, cash equivalents, and short-term investments, down from $140.2 million at the end of 2024.

  • Stock Movement: The company's stock dropped by 10% following a recent stock offering.

  • Clinical Trial Updates: Eledon Pharmaceuticals discussed the results of its Phase II BESTOW trial and advancements in transplantation immunosuppression.

[object Object]
Preview
9.0
11-08Benzinga
Eledon Pharmaceuticals' Key Asset Falls Short in Mid-Stage Trial, Yet Advances to Crucial Study

  • Stock Performance: Eledon Pharmaceuticals (NASDAQ: ELDN) experienced a significant drop in stock price, down 59.03% to $1.68, with a trading volume of 15.72 million shares compared to its average of 1.24 million.

  • Phase 2 Trial Results: The Phase 2 BESTOW trial for tegoprubart, aimed at preventing organ rejection in kidney transplant patients, did not show significant improvements in estimated glomerular filtration rates (eGFR) compared to the standard immunosuppressant tacrolimus.

  • Efficacy and Safety Findings: Despite missing the primary efficacy endpoint, tegoprubart demonstrated the highest mean eGFR reported in kidney transplant trials and showed lower rates of delayed graft function and shorter dialysis duration compared to tacrolimus.

  • Future Development Plans: Eledon plans to advance tegoprubart into Phase 3 development after discussions with regulators, supported by approximately $93.4 million in cash reserves expected to last until late 2026.

[object Object]
Preview
4.5
11-08Benzinga
Dow Falls More Than 200 Points; Fluor Stock Declines Following Q3 Earnings Report

  • U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones falling over 200 points, while the NASDAQ and S&P 500 also experienced significant drops. Consumer staples saw a rise of 1.1%, contrasting with a 1.8% decline in communication services stocks.

  • Company Earnings Reports: Fluor Corporation's shares fell 2% despite exceeding earnings expectations, while Motorsport Games Inc and BIO-Key International Inc saw substantial increases in their stock prices due to positive sales results and significant deployments, respectively.

  • Commodity Market Updates: Oil prices increased by 0.2% to $59.58, while gold and silver also saw slight gains. In contrast, copper prices fell by 0.2%.

  • Global Market Trends: European and Asian markets closed lower, with notable declines in major indices such as the STOXX 600 and Japan's Nikkei 225. Additionally, U.S. consumer sentiment dropped to 50.3 in November, indicating a decline in consumer confidence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN) stock price today?

The current price of ELDN is 1.59 USD — it has increased 0 % in the last trading day.

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN)'s business?

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

arrow icon

What is the price predicton of ELDN Stock?

Wall Street analysts forecast ELDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELDN is 7.75 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN)'s revenue for the last quarter?

Eledon Pharmaceuticals Inc revenue for the last quarter amounts to -19.07M USD, decreased -7.02 % YoY.

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN)'s earnings per share (EPS) for the last quarter?

Eledon Pharmaceuticals Inc. EPS for the last quarter amounts to -14477000.00 USD, increased 23.01 % YoY.

arrow icon

What changes have occurred in the market's expectations for Eledon Pharmaceuticals Inc (ELDN)'s fundamentals?

The market is revising No Change the revenue expectations for Eledon Pharmaceuticals, Inc. (ELDN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -41.33%.
arrow icon

How many employees does Eledon Pharmaceuticals Inc (ELDN). have?

Eledon Pharmaceuticals Inc (ELDN) has 31 emplpoyees as of December 05 2025.

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN) market cap?

Today ELDN has the market capitalization of 119.30M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free